Mar. 31 at 12:56 PM
It appears
$APLS $5.6B acquisition by Biogen was priced, more or less, consistent with peer commercial-stage M&A exits @ ~4X Year 4 estimates and at 0.35X 10-year estimates. This is in spite of APLS reported 85% gross margins in FY25 which is on the lower end versus peers.
This should be encouraging to
$BCRX investors hoping for a M&A exit. The STs community bashed APLS just like they bash BCRX. Projected revenues appear king.
The attachment compares APLS to peer comm'l-stage M&A exits.
Other M&A candidates per Betaville include:
$MDGL (but remember fully diluted shares O/S are ~35% higher than traditional shares O/S)
$PEN
$PRGS
As always, exercise caution & verify any attached data points for yourself. This is not investment advice.
